Recent Finacing
Recent Raise
Graybug Vision is a clinical-stage ophthalmology company developing long-acting intravitreal controlled-release therapies for retinal diseases (wet AMD, DME, RVO) and glaucoma, including GB-102 designed for twice-yearly dosing.
